Cnp prodrugs
AssigneeAscendis Pharma Growth Disorders A/S
InventorsKennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
Life of this patent
Estimating the term…
Abstract
The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
Claims21
A CNP prodrug or a pharmaceutically acceptable salt thereof, wherein the prodrug is of formula (Ia) or (Ib)
- ZL2-L1-D)x (Ia)
- DL1-L2-Z)y (Ib),
- wherein
- -D is a CNP moiety;
- -L1- is a reversible prodrug linker moiety;
- -L2- is a single chemical bond or a spacer moiety;
- —Z is a water-soluble carrier moiety;
- x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;
- and
- y is an integer selected from the group consisting of 1, 2, 3, 4 and 5.
A CNP prodrug or a pharmaceutically acceptable salt thereof comprising a conjugate D-L, wherein
- -D is a CNP moiety;
- and
- -L comprises a reversible prodrug linker moiety -L1-;
- wherein -L1- is substituted with -L2-Z′ and is optionally further substituted;
- wherein
- -L2- is a single chemical bond or a spacer moiety;
- and
- —Z′ is a water-insoluble carrier moiety.
21-59. (canceled)
Dependencies are inferred from the claim text.